Advancing MRD as a Surrogate Endpoint in Precision Oncology

• Evaluating the clinical and analytical validation required for MRD to serve as a reliable surrogate endpoint across tumor types
• Aligning trial design, assay sensitivity, and timepoint selection to generate robust, regulator-ready evidence
• Exploring how MRD-driven endpoints could accelerate development timelines and inform earlier treatment decisions

Speakers:

Melissa Reuter

Scientific Director, Global Diagnostic Lead

Johnson & Johnson